Anti-inflammatory compounds, pharmaceutical compositions, and methods of treating hemochromatosis and other disorders
AssigneeMiralogx LLC
InventorJonnie R. Williams, SR.
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compounds have anti-inflammatory activity. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. A method of treating hemochromatosis, hyperammonemia, or a disorder associated with chronic inflammation or a cancer, involves administering the pharmaceutical composition to an individual in need thereof. In another aspect, a method of inhibiting formation of metal oxides or reducing metal reactivity comprises contacting a metal with an effective amount of the compound(s).
Claims12
A compound having a structure of Formula VIIIa:
- or a pharmaceutically acceptable salt, ester or solvate thereof, wherein x is an integer from 1-4, y is an integer from 0-3, z is an integer from 0-4 with the proviso that y+z≥1, and the ring atoms of the six-membered ring and the five-membered ring(s) are optionally substituted at a substitutable position with —OH, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, or heterocycle;
- wherein the alkyl, alkenyl, alkynyl or acyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycle;
- wherein RA and RB are each independently selected from hydrogen and C1-4 alkyl;
- wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O)O—C1-4 alkyl, NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl;
- wherein RC and RD are each independently selected from hydrogen and C1-4 alkyl.
A compound having a structure of Formula VIIIb:
- or a pharmaceutically acceptable salt, ester or solvate thereof, wherein x is an integer from 1-4, y is 1 or 2 and the ring atoms of the six-membered ring and the five-membered ring(s) are optionally substituted at a substitutable position with OH, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, or heterocycle;
- wherein the alkyl, alkenyl, alkynyl or acyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycle;
- wherein RA and RB are each independently selected from hydrogen and C1-4 alkyl;
- wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O)O—C1-4 alkyl, NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl;
- wherein RC and RD are each independently selected from hydrogen and C1-4 alkyl.
Dependencies are inferred from the claim text.